{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:16:24Z","timestamp":1789697784284,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T00:00:00Z","timestamp":1441929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T00:00:00Z","timestamp":1441929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>Background<\/jats:italic> Lapatinib has proven efficacy as monotherapy and in combination with capecitabine in patients with metastatic breast cancer (MBC) overexpressing HER2 and\/or EGFR. Gemcitabine also has anti-tumor activity in MBC and a favourable toxicity profile. In this phase I study lapatinib and gemcitabine were combined. <jats:italic>Methods<\/jats:italic> Female patients with advanced BC were given lapatinib once daily (QD) in 28-day cycles with gemcitabine administered on day 1, 8 and 15. Physical examinations, vital signs and blood sampling for hematology, clinical chemistry and pharmacokinetics (PK) and radiological assessments of disease were performed at regular intervals. <jats:italic>Results<\/jats:italic> In total, 33 patients were included. Six dose-limiting toxicities were observed, mostly grade 3 increases in liver function tests. Most common toxicities were fatigue (73\u00a0%), nausea (70\u00a0%), diarrhea (58\u00a0%), increases in ALAT and ASAT (55 and 52\u00a0%, respectively) and rash (46\u00a0%). The maximum tolerated dose was lapatinib 1250\u00a0mg QD with gemcitabine 1000\u00a0mg\/m<jats:sup>2<\/jats:sup>. Lapatinib and gemcitabine PK did not appear to be influenced by each other. Anti-tumor activity was observed with one patient (4\u00a0%) showing complete response and six (23\u00a0%) partial response. <jats:italic>Conclusion<\/jats:italic> Despite a slightly increased toxicity profile compared to their respective monotherapies, lapatinib and gemcitabine can be safely combined while showing signs of anti-tumor activity.<\/jats:p>","DOI":"10.1007\/s10637-015-0281-z","type":"journal-article","created":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T05:49:31Z","timestamp":1441950571000},"page":"1197-1205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer"],"prefix":"10.1007","volume":"33","author":[{"given":"R.","family":"van der Noll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. N. M.","family":"Wymenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. S.","family":"Boss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Tibben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Keessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rehorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,11]]},"reference":[{"key":"281_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69\u201390","journal-title":"CA Cancer J Clin"},{"key":"281_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"key":"281_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127\u2013137","journal-title":"Nat Rev Mol Cell Biol"},{"key":"281_CR4","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","volume":"26","author":"MM Moasser","year":"2007","unstructured":"Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469\u20136487","journal-title":"Oncogene"},{"key":"281_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0149-2918(00)88288-0","volume":"21","author":"MM Goldenberg","year":"1999","unstructured":"Goldenberg MM (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21:309\u2013318","journal-title":"Clin Ther"},{"key":"281_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA (2007) Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 357:39\u201351","journal-title":"N Engl J Med"},{"key":"281_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273\u20131283","journal-title":"N Engl J Med"},{"key":"281_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/bcr1612","volume":"8","author":"R Nahta","year":"2006","unstructured":"Nahta R, Esteva FJ (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8:215","journal-title":"Breast Cancer Res"},{"key":"281_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1358\/dot.2006.42.7.985637","volume":"42","author":"SRD Johnston","year":"2006","unstructured":"Johnston SRD, Leary A (2006) Lapatinib: a novel EGFR\/HER2 tyrosine kinase inhibitor for cancer. Drugs Today 42:441\u2013453","journal-title":"Drugs Today"},{"key":"281_CR10","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1200\/JCO.2005.16.584","volume":"23","author":"HA Burris","year":"2005","unstructured":"Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O\u2019Neil B et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305\u20135313","journal-title":"J Clin Oncol"},{"key":"281_CR11","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/annonc\/mdm601","volume":"19","author":"HJ Burstein","year":"2008","unstructured":"Burstein HJ, Storniolo AM, Franco S, Forster J, Stein S, Rubin S et al (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19:1068\u20131074","journal-title":"Ann Oncol"},{"key":"281_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(09)70087-7","volume":"10","author":"B Kaufman","year":"2009","unstructured":"Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V et al (2009) Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 10:581\u2013588","journal-title":"Lancet Oncol"},{"key":"281_CR13","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/annonc\/mdn759","volume":"20","author":"KL Blackwell","year":"2009","unstructured":"Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD et al (2009) Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 20:1026\u20131031","journal-title":"Ann Oncol"},{"key":"281_CR14","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1634\/theoncologist.2008-0816","volume":"13","author":"Q Ryan","year":"2008","unstructured":"Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko C, Sridhara R et al (2008) FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 13:1114\u20131119","journal-title":"Oncologist"},{"key":"281_CR15","unstructured":"European Medicines Agency. Tyverb lapatinib. 2013 (2008) http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000795\/human_med_001120.jsp&mid=WC0b01ac058001d124. Accessed 1 April 2014"},{"key":"281_CR16","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733\u20132743","journal-title":"N Engl J Med"},{"key":"281_CR17","first-page":"3","volume":"22","author":"W Plunkett","year":"1995","unstructured":"Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3\u201310","journal-title":"Semin Oncol"},{"key":"281_CR18","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris","year":"1997","unstructured":"Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"key":"281_CR19","unstructured":"Food and Drug Administration. Gemzar (2006) http:\/\/www.cancer.gov\/aboutcancer\/treatment\/drugs\/fda-gemcitabine-hydrochloride. Accessed 1 April 2014"},{"key":"281_CR20","unstructured":"European Medicines Agency. Gemzar (2008) http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Gemzar\/human_referral_000031.jsp. Accessed 1 April 2014"},{"key":"281_CR21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.1999.17.1.12","volume":"17","author":"F Cardenal","year":"1999","unstructured":"Cardenal F, L\u00f3pez-Cabrerizo MP, Ant\u00f3n A, Alberola V, Massuti B, Carrato A et al (1999) Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17:12\u201318","journal-title":"J Clin Oncol"},{"key":"281_CR22","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H Von der Maase","year":"2005","unstructured":"Von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602\u20134608","journal-title":"J Clin Oncol"},{"key":"281_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1054\/brst.2000.0170","volume":"9","author":"T Brodowicz","year":"2000","unstructured":"Brodowicz T, Kostler WJ, M\u00f6slinger R, Tomek S, Vaclavik I, Herscovici V et al (2000) Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 9:338\u2013342","journal-title":"Breast"},{"key":"281_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000048240","volume":"62","author":"M Blackstein","year":"2002","unstructured":"Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A (2002) Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62:2\u20138","journal-title":"Oncology"},{"key":"281_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176\u2013181","journal-title":"Semin Radiat Oncol"},{"key":"281_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/bmc.2814","volume":"27","author":"NAG Lankheet","year":"2013","unstructured":"Lankheet NAG, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH, Huitema ADR (2013) Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 27:466\u2013476","journal-title":"Biomed Chromatogr"},{"key":"281_CR27","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1158\/1078-0432.CCR-07-4521","volume":"14","author":"SA Veltkamp","year":"2008","unstructured":"Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H et al (2008) Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 14:3477\u20133486","journal-title":"Clin Cancer Res"},{"key":"281_CR28","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/jms.1133","volume":"41","author":"SA Veltkamp","year":"2006","unstructured":"Veltkamp SA, Hillebrand MJX, Rosing H, Jansen RS, Wickremsinhe ER, Perkins EJ et al (2006) Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. J Mass Spectrom 41:1633\u20131642","journal-title":"J Mass Spectrom"},{"key":"281_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"281_CR30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","volume":"9","author":"JL Abbruzzese","year":"1991","unstructured":"Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491\u2013498","journal-title":"J Clin Oncol"},{"key":"281_CR31","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.1999.17.7.2190","volume":"17","author":"JR Kroep","year":"1999","unstructured":"Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H et al (1999) Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17:2190\u20132197","journal-title":"J Clin Oncol"},{"key":"281_CR32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/COC.0b013e318145b9a5","volume":"31","author":"H Safran","year":"2008","unstructured":"Safran H, Miner T, Resnick M, Dipetrillo T, McNulty B, Evans D et al (2008) Lapatinib\/gemcitabine and lapatinib\/gemcitabine\/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. Am J Clin Oncol 31:140\u2013144","journal-title":"Am J Clin Oncol"},{"key":"281_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/COC.0b013e3181d26b01","volume":"34","author":"H Safran","year":"2011","unstructured":"Safran H, Miner T, Bahary N, Whiting S, Lopez CD, Sun W et al (2011) Lapatinib and gemcitabine for metastatic pancreatic cancer. Am J Clin Oncol 34:50\u201352","journal-title":"Am J Clin Oncol"},{"key":"281_CR34","first-page":"1484","volume":"60","author":"A Murata","year":"2013","unstructured":"Murata A, Nakata B, Komoto M, Hirata K, Kimura K, Amano R et al (2013) In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells. Hepatogastroenterology 60:1484\u20131487","journal-title":"Hepatogastroenterology"},{"key":"281_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3747\/co.v17i2.422","volume":"17","author":"JM Gasent Blesa","year":"2010","unstructured":"Gasent Blesa JM, Laforga Canales J, Candel VA (2010) One year of complete clinical response in a metastatic breast cancer patient treated with a combination of lapatinib and gemcitabine. Curr Oncol 17:64\u201368","journal-title":"Curr Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0281-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-015-0281-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0281-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0281-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:48:03Z","timestamp":1678510083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-015-0281-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["281"],"URL":"https:\/\/doi.org\/10.1007\/s10637-015-0281-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,11]]},"assertion":[{"value":"29 May 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}